NASDAQ
27.00USD
0.00 (0.00%)
We have scored 7 news catalysts on KalVista Pharmaceuticals, Inc. (KALV) over the past 12 months. The biggest single-day move next to one of them came Dec 4, 2025, when KALV closed +11.9%: “Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals”. Coverage across the window leans positive (average ticker sentiment +0.33). Most of the impact sits in short squeeze potential and sector healthcare.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
1.4B
P/E
—
EPS
—
Beta
-0.29
52W range
9.83-27
Day range
26.98–27.00
Open
26.98
Prev close
27.00
Volume
4.3M
Avg volume
3.5M
Dividend
0.00
IPO
2015-04-09
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about KalVista Pharmaceuticals, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for KALV: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Framingham, MA.
